JP7796016B2 - 組成物および過敏症のための指示 - Google Patents

組成物および過敏症のための指示

Info

Publication number
JP7796016B2
JP7796016B2 JP2022536602A JP2022536602A JP7796016B2 JP 7796016 B2 JP7796016 B2 JP 7796016B2 JP 2022536602 A JP2022536602 A JP 2022536602A JP 2022536602 A JP2022536602 A JP 2022536602A JP 7796016 B2 JP7796016 B2 JP 7796016B2
Authority
JP
Japan
Prior art keywords
individual
pharmaceutical composition
administered
therapeutically effective
ocular surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022536602A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510499A5 (https=
JP2023510499A (ja
Inventor
アルスター，ヤイル
ボスワース，チャールズ
エプスタイン－バラッシュ，ヒラ
ラファエリ，オマー
Original Assignee
アズーラ オフサルミックス エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アズーラ オフサルミックス エルティーディー． filed Critical アズーラ オフサルミックス エルティーディー．
Publication of JP2023510499A publication Critical patent/JP2023510499A/ja
Publication of JP2023510499A5 publication Critical patent/JP2023510499A5/ja
Priority to JP2025273955A priority Critical patent/JP2026052691A/ja
Application granted granted Critical
Publication of JP7796016B2 publication Critical patent/JP7796016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022536602A 2020-01-10 2021-01-07 組成物および過敏症のための指示 Active JP7796016B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025273955A JP2026052691A (ja) 2020-01-10 2025-12-22 組成物および過敏症のための指示

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062959738P 2020-01-10 2020-01-10
US62/959,738 2020-01-10
PCT/IB2021/000005 WO2021140417A2 (en) 2020-01-10 2021-01-07 Instructions for composition and sensitivity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025273955A Division JP2026052691A (ja) 2020-01-10 2025-12-22 組成物および過敏症のための指示

Publications (3)

Publication Number Publication Date
JP2023510499A JP2023510499A (ja) 2023-03-14
JP2023510499A5 JP2023510499A5 (https=) 2024-01-17
JP7796016B2 true JP7796016B2 (ja) 2026-01-08

Family

ID=76787770

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022536602A Active JP7796016B2 (ja) 2020-01-10 2021-01-07 組成物および過敏症のための指示
JP2025273955A Pending JP2026052691A (ja) 2020-01-10 2025-12-22 組成物および過敏症のための指示

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025273955A Pending JP2026052691A (ja) 2020-01-10 2025-12-22 組成物および過敏症のための指示

Country Status (6)

Country Link
US (3) US11517586B2 (https=)
EP (1) EP4087655A4 (https=)
JP (2) JP7796016B2 (https=)
CN (1) CN115279458A (https=)
CA (1) CA3166357A1 (https=)
WO (1) WO2021140417A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021090070A2 (en) * 2019-11-04 2021-05-14 Azura Ophthalmics Ltd. Metered dose for disorders in or around the eye
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
WO2025012701A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Administration of keratolytics to ocular and periocular surfaces

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531668A (ja) 2014-10-19 2017-10-26 エム．ジー．セラピューティクス エルティーディー． マイボーム腺機能不全の処置のための組成物及び方法

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3236730A (en) * 1962-01-04 1966-02-22 Miles Lab Blepharitis composition comprising antiseptic, quaternary ammonium compound, keratolytic agent and a chelating compound
US5602130A (en) 1987-03-20 1997-02-11 Allergan Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
SG52678A1 (en) 1992-05-20 1998-09-28 Karen E Burke A method for the reversal of extrinsic aging of the skin by transdermal application of selenoamino acids and compositions therefore
US5645827A (en) 1992-09-30 1997-07-08 Union Carbide Chemicals & Plastics Technology Corporation Muco-adhesive polymers
JP2891883B2 (ja) 1993-11-05 1999-05-17 学校法人近畿大学 抗白内障医薬組成物
US5897539A (en) 1995-09-28 1999-04-27 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
WO1997020578A1 (en) 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US5965606A (en) 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
FR2756493B1 (fr) 1996-12-02 2001-04-13 Delab Dispositif d'administration locale de formulations solides ou semi-solides
EP0930072A1 (en) 1998-01-13 1999-07-21 Kartar Dr. Lalvani Vitamin and mineral containing compositions for the treatment of dry eye
US6011067A (en) 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US6348508B1 (en) 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
AUPQ877300A0 (en) 2000-07-13 2000-08-03 Johnson & Johnson Pacific Pty Limited Topical treatment of skin
US6495158B1 (en) 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US20020127256A1 (en) 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
FR2832637B1 (fr) 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
FR2833268B1 (fr) 2001-12-12 2005-07-08 Fabre Pierre Dermo Cosmetique Nouvelle association contenant un poloxamer et de l'acide chondroitine sulfurique et/ou une glycoproteine et son utilisation
KR100564386B1 (ko) 2002-05-13 2006-03-27 주식회사 마이코플러스 4-하이드록시-5-메톡시-4-[2-메틸-3-(3-메틸-2-부테닐)-2-옥시란닐]-1-옥사스피로[2,5]옥탄-6-온을 함유한 지루치료용 약제학적 조성물
US20030224028A1 (en) 2002-05-13 2003-12-04 Societe L'oreal S.A. Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal
US8420699B1 (en) 2002-06-19 2013-04-16 Irvine L. Dubow Composition and methods of treatment using deionized and ozonated solution
EP1531793A1 (en) 2002-07-23 2005-05-25 Novartis AG Ophtalmic ointment composition comprising a drug, an ointment base and a solubiling/dispersing agent
EP2272340B1 (en) 2002-08-19 2018-03-14 Ira Sanders Botulinum toxin
US20040171561A1 (en) 2002-09-03 2004-09-02 Popp Karl F. Topical formulations for treatment of rosacea
EP1551399A4 (en) 2002-09-30 2011-01-05 Mark A Babizhayev METHOD FOR THE TOPICAL TREATMENT OF EYE DISEASES AND COMPOSITION AND DEVICE FOR THIS TREATMENT
US20060188471A1 (en) 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
GB0225795D0 (en) 2002-11-05 2002-12-11 Guillon Michael Wipes
US20070269537A1 (en) 2003-02-10 2007-11-22 Bioderm Research Skin Condition Improvement Including Acne, Rosacea, and Topical Wounds by Artemisia Annua Extract via Iron Siderophore Trojan Horse Delivery System
US20040220167A1 (en) * 2003-05-02 2004-11-04 Nasrollah Samiy Methods of treating neuralgic pain
GB0322448D0 (en) 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US20070082017A1 (en) 2004-01-10 2007-04-12 Tseng Scheffer C Lipid compositions and methods of use
US20080025929A1 (en) 2004-02-19 2008-01-31 Chemaphor, Inc. Topical Formulations for the Treatment of Skin Conditions
GB0404693D0 (en) 2004-03-02 2004-04-07 Univ London Pharmaceutical preparations for the treatment of ocular surface and other disorders
US20050197614A1 (en) 2004-03-04 2005-09-08 Wilson Pritchard Occlusive biomedical devices, punctum plugs, and methods of use thereof
US20050202097A1 (en) 2004-03-12 2005-09-15 Melbj Holdings, Llc, Florida Lubricant for the ocular surface
US8455016B2 (en) * 2004-03-12 2013-06-04 Melbj Holdings, Llc Treatment for meibomian gland dysfunction or obstruction
US20060051396A1 (en) 2004-06-16 2006-03-09 Affinergy, Inc. Biofunctional coatings
WO2006014484A2 (en) * 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
EP1621191A1 (en) 2004-07-29 2006-02-01 Werner Bollag Treatment of inflammatory diseases by RXR Antagonists
PT1791423E (pt) 2004-08-02 2013-08-02 Sami Labs Ltd Composições e métodos para o tratamento de condições dermatológicas hiperproliferativas
US7776915B2 (en) 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20090214676A1 (en) 2005-04-30 2009-08-27 Tissuetech, Inc. Method for treating ocular demodex
CN101203236A (zh) 2005-06-22 2008-06-18 坪田一男 角结膜疾病的预防或治疗剂
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
WO2007070463A2 (en) 2005-12-12 2007-06-21 Riolan Technologies, Inc. Compositions, methods and kits for removing debris from an ocular area
CA2651815A1 (en) 2006-05-10 2007-11-22 Dxterity Diagnostics Detection of nucleic acid targets using chemically reactive oligonucleotide probes
WO2007137369A1 (en) 2006-05-31 2007-12-06 Medihoney Pty Ltd Medicinal compositions containing honey
WO2008027069A1 (en) 2006-08-21 2008-03-06 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction employing fluid
US8249695B2 (en) 2006-09-29 2012-08-21 Tearscience, Inc. Meibomian gland imaging
US8090426B2 (en) 2006-10-27 2012-01-03 Felder Robin A Microelectronic biosensor plug
US20080102122A1 (en) * 2006-10-31 2008-05-01 Shivkumar Mahadevan Antimicrobial polymeric articles, processes to prepare them and methods of their use
US20100204317A1 (en) 2006-11-03 2010-08-12 Qlt Inc. Methods of treating dermatological disorders or conditions
WO2008068866A1 (en) 2006-11-30 2008-06-12 Menicon Co., Ltd. Ophthalmic composition
BRPI0808410A2 (pt) 2007-02-28 2015-06-23 Aciex Therapeutics Inc Métodos e composições para normalizar secreções da glândula meibomiana
EP2136800A4 (en) 2007-03-19 2011-10-05 Wisconsin Alumni Res Found MODULATION OF BACTERIAL QUORUM DETECTION WITH SYNTHETIC LIGANDS
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
ES2667945T3 (es) 2007-10-08 2018-05-16 Aurinia Pharmaceuticals Inc. Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
WO2009120881A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin desease using tetracycline family antibiotics
CN104623741A (zh) 2008-04-30 2015-05-20 马缇医疗股份有限公司 复合泪管植入物及相关方法
JP5661035B2 (ja) 2008-07-10 2015-01-28 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 眼および皮膚の疾患および症状の治療用のシクロスポリン誘導体
WO2010033800A2 (en) 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
US9888839B2 (en) 2009-04-01 2018-02-13 Tearscience, Inc. Methods and apparatuses for determining contact lens intolerance in contact lens wearer patients based on dry eye tear film characteristic analysis and dry eye symptoms
CA2760591C (en) 2009-05-01 2018-01-02 Advanced Vision Research, Inc. Cleanser compositions and methods for using the same
CN101612161A (zh) 2009-08-07 2009-12-30 魏谠全 一种眼药组合物及其制剂
US20130064788A1 (en) 2009-10-10 2013-03-14 Eleven Biotherapeutics, Inc. Il-17 family cytokine compositions and uses
US9034830B2 (en) 2009-10-30 2015-05-19 Intratus, Inc. Methods and compositions for sustained delivery of drugs
US20110294897A1 (en) 2009-12-02 2011-12-01 Bridge Pharma, Inc. Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
US8304840B2 (en) 2010-07-29 2012-11-06 Taiwan Semiconductor Manufacturing Company, Ltd. Spacer structures of a semiconductor device
US20120093876A1 (en) 2010-10-13 2012-04-19 Aciex, Inc. Ophthalmic Formulations, Methods Of Manufacture And Methods of Normalizing Meibomian Gland Secretions
AU2011327785A1 (en) 2010-11-08 2013-03-07 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
WO2012092378A1 (en) 2010-12-29 2012-07-05 Inspire Pharmaceuticals, Inc. Method for treating blepharitis
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
US20130281390A1 (en) 2010-12-29 2013-10-24 Kurt E. Brubaker Method for treating dry eye
KR101914940B1 (ko) 2011-01-26 2018-11-06 알러간, 인코포레이티드 안과 질환을 치료하기 위한 안드로겐 조성물
JP6072009B2 (ja) 2011-05-12 2017-02-01 フォーサイト・バイオセラピューティクス・インコーポレーテッド ステロイド又は非ステロイド性抗炎症薬のある安定なポビドンヨード組成物
EP2711374A4 (en) 2011-05-20 2014-05-21 Univ Keio NEW METAL PROTEIN AND METHOD FOR THE PRODUCTION THEREOF, AND PROPHYLACTIC OR THERAPEUTIC AGENT AGAINST HORN OR BINDING DAMAGE WITH THIS METAL PROTEIN
CA2840626A1 (en) 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
US9510972B2 (en) 2012-01-04 2016-12-06 Sight Sciences, Inc. Dry eye treatment systems
ITFI20120044A1 (it) 2012-03-01 2013-09-02 Biodue Spa Formulazione ad uso oftalmico comprendente olio di jojoba.
EP2838547B1 (en) 2012-04-16 2019-09-04 Lubrizol Advanced Materials, Inc. Compounds for the treatment and/or care of the skin and/or mucous membranes and their use in cosmetic or pharmaceutical compositions
AU2013299785B2 (en) 2012-08-06 2017-09-07 Baylor College Of Medicine Therapeutics dispensing device and methods of making same
US9238018B2 (en) 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
US10500255B2 (en) 2012-12-21 2019-12-10 Aqua Bio Technology Asa Cosmetic compositions from fish hatching fluid
CA2898644A1 (en) 2013-01-24 2014-07-31 Rigel Pharmaceuticals, Inc. Composition for ophthalmic administration
US9987235B2 (en) 2013-08-01 2018-06-05 Nicholas L. Abbott Methods and compositions for modifying mucous membranes
HUE14755117T2 (hu) 2013-08-14 2018-12-28 Kalvista Pharmaceuticals Ltd Plazma-kallikrein inhibitorok
EP3055003B1 (en) 2013-10-07 2019-04-24 Ocuject, LLC Intraocular delivery devices
EP3139903B1 (en) 2014-05-07 2019-07-03 Croma-Pharma Gesellschaft m.b.H. Aqueous ophthalmic solution and method for treating dry eye syndrome
US9668996B2 (en) 2014-06-04 2017-06-06 Tersus Life Sciences, LLC Methods of treating chronic dry eye disease using C16:1n7-palmitoleate and derivatives thereof
WO2016042163A2 (en) 2014-09-19 2016-03-24 Medterials, Inc. Ophthalmic drug compositions
US20160199405A1 (en) 2015-01-12 2016-07-14 Paul Sutich Method and Topical Composition for the Treatment of Rosacea and Skin Erythema Using Selenium Sulfide
ES2830152T3 (es) 2015-03-03 2021-06-03 Nof Corp Colirios
WO2016196989A1 (en) * 2015-06-03 2016-12-08 Senju Usa, Inc. Topical composition
US10688122B2 (en) 2015-09-28 2020-06-23 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
CN105456287B (zh) 2015-12-03 2017-06-30 大有药业扬州有限公司 二硫化硒超微粉体及其制备方法
CN205459330U (zh) 2016-02-04 2016-08-17 张晨明 赶压式睑板腺功能障碍治疗装置
US11040062B2 (en) * 2016-04-14 2021-06-22 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
JP2019513775A (ja) 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
EP3600272A4 (en) 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
US10512671B2 (en) * 2017-04-19 2019-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services IL-24 to treat inflammatory diseases
EP3833631A4 (en) 2018-08-10 2022-04-20 Azura Ophthalmics Ltd DISPENSER FOR ACCURATE EXTRACTION OF A SEMI-SOLID PRODUCT
JP7723603B2 (ja) 2019-04-12 2025-08-14 アズーラ オフサルミックス エルティーディー． コンタクトレンズ不快感を処置するための組成物および方法
CA3142608A1 (en) * 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
WO2021090058A2 (en) 2019-11-04 2021-05-14 Azura Ophthalmics Ltd. Metered dose for demodex and disorders related thereto
WO2021090070A2 (en) 2019-11-04 2021-05-14 Azura Ophthalmics Ltd. Metered dose for disorders in or around the eye
JP2023513415A (ja) 2020-01-02 2023-03-31 アズーラ オフサルミックス エルティーディー． 二硫化セレン組成物の製造
WO2021140419A1 (en) 2020-01-08 2021-07-15 Azura Ophthalmics Ltd. Device for administering drug to eyelid
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017531668A (ja) 2014-10-19 2017-10-26 エム．ジー．セラピューティクス エルティーディー． マイボーム腺機能不全の処置のための組成物及び方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
American Journal of Ophthalmology，1954年，Vol.38, No.4，p.560-562
Indian Journal of Ophthalmology，2018年，Vol.66, No.1，p.36-38
あたらしい眼科，2017年，Vol.34, No.2，p.227-228 (p.85-86)

Also Published As

Publication number Publication date
WO2021140417A3 (en) 2021-08-26
US11517586B2 (en) 2022-12-06
US20210401877A1 (en) 2021-12-30
EP4087655A4 (en) 2024-02-21
JP2026052691A (ja) 2026-03-24
CA3166357A1 (en) 2021-07-15
WO2021140417A2 (en) 2021-07-15
US20220409657A1 (en) 2022-12-29
US20230346832A1 (en) 2023-11-02
EP4087655A2 (en) 2022-11-16
JP2023510499A (ja) 2023-03-14
CN115279458A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
US20230346832A1 (en) Instructions for composition and sensitivity
ES2627405T3 (es) Composiciones que comprenden brimonidina para el tratamiento del eritema
ES2460578T3 (es) Uso de EDTA+trometamina o de foto-potenciadores, asociados a la riboflavina, para la reticulación de la córnea en el tratamiento del queratocono o de otros trastornos ectásicos de la córnea
JP5583310B2 (ja) 眼球の症状の予防及び治療のための眼科用製剤
CA2742973C (en) Use of low dosages of lipoic acid in the treatment of ocular disorders
US20100204335A1 (en) Kit and composition for eyelash growth
ES2730411T3 (es) Composiciones mejoradas que comprenden brimonidina para un tratamiento seguro y eficaz de la telangiectasia
KR20110017365A (ko) 피부 염증 및 변색을 위한 방법 및 조성물
US11369812B2 (en) Non-irritating, non-blurring ophthalmic sunscreen
KR20040105706A (ko) 화학적 예방 활성을 나타내는 비스테로이드계 소염제를함유하는 국소 제형
ES2742851T3 (es) Tratamiento y profilaxis de la dermatitis por radiación
JP2023510499A5 (https=)
CN104053425B (zh) 基于胶体银和脱氧核糖核酸的协同组合的医学护肤组合物
TWI896143B (zh) 一種有效延緩及治療近視的藥物組合物
WO2017075019A1 (en) Eye drops
RU2460502C1 (ru) Способ лечения возрастной начинающейся катаракты
JP2025519647A (ja) ドライアイ疾患の治療のためのｐｅｄｆ由来短鎖ペプチドを含む組成物
Rudnicka et al. of the Polish Dermatological Society. Part 2. Treatment
WO2020152527A1 (en) Ophthalmic pharmaceutical compositions based on vitamins, amino acids and minerals for treating immature cataract
BR112021011023A2 (pt) Microemulsões de vitamina d e suas utilizações
Agent L3T 7V9
US20150352026A1 (en) Composition for increasing of the effectiveness of uv-b therapy, process for the preparation thereof, and its use
Dupont FC039 Incidence of psoriatic arthropathy
HK1190067A (en) Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220708

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250626

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251222

R150 Certificate of patent or registration of utility model

Ref document number: 7796016

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150